Diagnostic utility of trefoil factor families for the early detection of lung cancer and their correlation with tissue expression.
ELISA
TFF
biomarker
immunohistochemistry
lung carcinoma
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
27
07
2022
accepted:
22
12
2022
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
Trefoil factors (TFFs) are upregulated in numerous types of cancer, including those of the breast, the colon, the lung and the pancreas, suggesting their potential utility as biomarkers for screening. In the present study, the clinical relevance of serum or urinary TFFs as biomarkers were comprehensively evaluated and the correlation with TFF expression levels in lung cancer tissue was examined. Serum and urine were collected from 199 patients with lung cancer and 198 healthy individuals. Concentrations of serum and urinary TFF1, TFF2 and TFF3 were measured using ELISA and the potential of TFF levels to discriminate between cancer and non-cancer samples was evaluated. In 100 of the cancer cases, expression of TFF1-3 was analyzed using immunohistochemical staining of paraffin sections. Furthermore, the relationship between TFF levels and clinicopathological factors among these cancer cases was analyzed using immunohistochemistry of tissue specimens, quantified and statistically analyzed. While serum levels of all TFFs measured using ELISA were significantly higher in patients with lung cancer compared with those in healthy individuals, urinary TFFs were lower. Areas under the curve (AUC) of the receiver operating characteristic curves for serum/urinary TFF1, TFF2 and TFF3 were 0.709/0.594, 0.722/0.501 and 0.663/0.665, respectively. Furthermore, the combination of serum TFF1, TFF2, TFF3 and urinary TFF1 and TFF3 demonstrated the highest AUC (0.826). In the clinicopathological analysis, serum TFF1 was higher in the early pathological T-stage (pTis/1/2) compared with the later stage (pT3/4) and TFF2 was higher in the pN0/1 than the pN2 group. With regards to the histological types, urinary TFF1 was higher in squamous cell carcinoma than adenocarcinoma (AC), but TFF2 tended to be higher in AC. Using immunohistochemical analysis, although TFF1 and TFF3 expression showed positive correlation with serum concentrations, TFF2 was inversely correlated. In conclusion, serum and urinary TFF levels are promising predictive biomarkers, and their measurements provide a useful
Identifiants
pubmed: 36909373
doi: 10.3892/ol.2023.13725
pii: OL-25-4-13725
pmc: PMC9996639
doi:
Types de publication
Journal Article
Langues
eng
Pagination
139Informations de copyright
Copyright: © Minegishi et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
PLoS One. 2015 Jun 17;10(6):e0126924
pubmed: 26083576
Cell Mol Life Sci. 2004 Aug;61(15):1946-54
pubmed: 15289936
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):799-804
pubmed: 10639160
Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1330-5
pubmed: 10194185
Dis Markers. 2018 Dec 11;2018:9845123
pubmed: 30647803
Oncogene. 2006 Oct 26;25(50):6628-36
pubmed: 16715141
Gastroenterology. 2000 Jan;118(1):60-9
pubmed: 10611154
BMC Clin Pathol. 2014 Jun 14;14:26
pubmed: 25031551
Cell Physiol Biochem. 2007;20(6):899-908
pubmed: 17982272
Respirology. 2005 Jan;10(1):97-104
pubmed: 15691245
Clin Chim Acta. 2015 Oct 23;450:127-34
pubmed: 26265233
Neoplasia. 2010 Dec;12(12):1041-53
pubmed: 21170268
J Gastroenterol. 2011 Jun;46(6):736-45
pubmed: 21455714
Am J Physiol. 1999 Oct;277(4):G785-95
pubmed: 10516144
World J Gastroenterol. 2017 Mar 28;23(12):2159-2167
pubmed: 28405143
Dig Dis Sci. 2000 Apr;45(4):659-64
pubmed: 10759231
Int J Cancer. 1997 Jun 20;74(3):270-4
pubmed: 9221803
Br J Cancer. 2001 Jan 5;84(1):25-32
pubmed: 11139308
J Pathol. 2000 Feb;190(2):133-42
pubmed: 10657010
Breast Cancer Res. 2014 Sep 30;16(5):429
pubmed: 25266665
Cell Physiol Biochem. 2005;16(1-3):31-42
pubmed: 16121031
Neoplasma. 2015;62(3):470-7
pubmed: 25866228
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Br J Cancer. 2008 Sep 2;99(5):768-73
pubmed: 18682706
Clin Cancer Res. 2013 Apr 15;19(8):2240-7
pubmed: 23470965
J Cancer Res Ther. 2013 Jul-Sep;9(3):376-80
pubmed: 24125969
Cancer Sci. 2015 Jun;106(6):772-81
pubmed: 25855050
Oncogene. 2011 Jul 21;30(29):3261-73
pubmed: 21358676
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Pancreas. 2011 Aug;40(6):815-22
pubmed: 21747314
Clin Cancer Res. 2005 Sep 15;11(18):6472-8
pubmed: 16166422
Am J Respir Crit Care Med. 2002 Feb 15;165(4):508-13
pubmed: 11850344
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):807-12
pubmed: 16467092
Am J Pathol. 2012 Mar;180(3):904-916
pubmed: 22341453
Cell Mol Life Sci. 1997 Dec;53(11-12):888-903
pubmed: 9447240
J Cell Biol. 2002 May 27;157(5):761-70
pubmed: 12034770
Cell Mol Life Sci. 2009 Apr;66(8):1350-69
pubmed: 19099184
World J Gastroenterol. 2017 Jan 7;23(1):110-120
pubmed: 28104986
Clin Cancer Res. 2002 May;8(5):1092-9
pubmed: 12006524
Cell Death Dis. 2022 Jan 17;13(1):62
pubmed: 35039476
Int J Oncol. 2019 Oct;55(4):789-804
pubmed: 31432157
Nat Rev Cancer. 2007 Mar;7(3):169-81
pubmed: 17318210
BMC Gastroenterol. 2014 Apr 11;14:74
pubmed: 24720760
Sci Rep. 2017 Jul 7;7(1):4846
pubmed: 28687783
Lab Invest. 2003 Sep;83(9):1343-52
pubmed: 13679442
Gastroenterology. 2011 Sep;141(3):837-845.e1-7
pubmed: 21699780
Int J Mol Sci. 2020 Jun 25;21(12):
pubmed: 32630599
Radiology. 2003 Mar;226(3):756-61
pubmed: 12601181
Br J Cancer. 1998;77(3):492-6
pubmed: 9472649
Onco Targets Ther. 2021 Sep 10;14:4761-4777
pubmed: 34531663
Pathobiology. 2010;77(2):53-63
pubmed: 20332665
Histopathology. 2020 May;76(6):898-905
pubmed: 31985086
Int J Med Sci. 2013;10(2):133-40
pubmed: 23329884
J Proteome Res. 2010 Jan;9(1):545-55
pubmed: 19924834
Cell Physiol Biochem. 2014;33(4):895-904
pubmed: 24713603
Rev Esp Med Nucl. 2002 Apr;21(2):109-14
pubmed: 11879619
Histol Histopathol. 2007 Jul;22(7):743-51
pubmed: 17455148
Dis Markers. 2020 Dec 10;2020:4716793
pubmed: 33488842
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Br J Cancer. 2010 Jun 8;102(12):1681-6
pubmed: 20424610
Lung Cancer. 2000 Sep;29(3):197-203
pubmed: 10996422
Oncol Rep. 2021 Jan;45(1):254-264
pubmed: 33210724
Anticancer Res. 1996 Jul-Aug;16(4B):2351-5
pubmed: 8694568
Cell Mol Life Sci. 2005 Dec;62(24):2939-46
pubmed: 16374582
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1151-8
pubmed: 22516806
Oncol Rep. 2012 Apr;27(4):1277-83
pubmed: 22246423
Clin Exp Metastasis. 2009;26(2):143-51
pubmed: 18979216
Int J Mol Sci. 2021 May 06;22(9):
pubmed: 34066339
Biochim Biophys Acta. 1998 Aug 19;1378(1):F61-77
pubmed: 9739760
Biochem J. 1996 Sep 15;318 ( Pt 3):939-44
pubmed: 8836141
Technol Cancer Res Treat. 2017 Aug;16(4):440-445
pubmed: 27760866
Int J Mol Sci. 2019 Dec 09;20(24):
pubmed: 31835445